Compare CCSI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | LXRX |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.4M | 660.9M |
| IPO Year | 2022 | 2000 |
| Metric | CCSI | LXRX |
|---|---|---|
| Price | $25.24 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $37.50 | $4.15 |
| AVG Volume (30 Days) | 107.2K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ 4.35 | N/A |
| Revenue | ★ $349,696,000.00 | $49,803,000.00 |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $17.84 | $0.49 |
| 52 Week High | $31.67 | $1.86 |
| Indicator | CCSI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 64.34 |
| Support Level | $25.07 | $1.07 |
| Resistance Level | $26.62 | N/A |
| Average True Range (ATR) | 1.04 | 0.10 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 74.38 | 98.61 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in fax cloud business. The Company operates in USA, Canada, Ireland, and Other. Geographically, it derives a maximum revenue from the United States. The company's communication and digital signature solutions enable customers to securely and cooperatively access, exchange and use information across organizational, regional, and national boundaries.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.